Maricann Group (CNSX:MARI – Get Free Report) had its price objective upped by analysts at Raymond James from $6.00 to $6.50 in a report released on Tuesday, BayStreet.CA reports.
Separately, Canaccord Genuity Group dropped their target price on shares of Maricann Group from $6.50 to $6.00 and set a “speculative buy” rating for the company in a report on Friday, January 12th.
View Our Latest Report on Maricann Group
Maricann Group Stock Performance
About Maricann Group
Maricann Group Inc, formerly Danbel Industries Corporation, is a Canada-based integrated producer and distributor of marijuana for medical purposes. As one of approximately 43 companies with a federal license to cultivate cannabis and one of approximately 30 independent licensed producers with a federal license to process and distribute cannabis, the Company’s services a patient base with more than 8,000 registered patients.
Read More
- Five stocks we like better than Maricann Group
- What Investors Need to Know About Upcoming IPOs
- High-Yield Texas Instruments Could Hit New Highs Soon
- The 3 Best Fintech Stocks to Buy Now
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- What Are the U.K. Market Holidays? How to Invest and Trade
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Maricann Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maricann Group and related companies with MarketBeat.com's FREE daily email newsletter.